Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumours (MK-8353-014)

Official Title

Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumours

Summary:

This is a multicentre, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumour. This study will evaluate the safety, tolerability, and preliminary efficacy of MK-8353 in combination with selumetinib.

Trial Description

Primary Outcome:

• Number of Participants with a Dose Limiting Toxicity (DLT)
• Number of Participants with one or more Adverse Events (AEs)
• Number of Participants with a Study Drug Discontinuations due to an AE

• Area Under the Plasma Concentration-Time Curve (AUC) for MK-8353
• Minimum Observed Plasma Concentration (Cmin) for MK-8353
• Maximum Observed Plasma Concentration (Cmax) for MK-8353
• AUC for Selumetinib
• Cmin for Selumetinib
• Cmax for Selumetinib

View this trial on ClinicalTrials.gov